Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

[Expert consensus on combined screening for common cancers(2025 edition)].

Zhonghua zhong liu za zhi [Chinese journal of oncology]·2025

Same author

[Regional disparities in trends of global gastric cancer incidence and mortality from 1990 to 2019].

Zhonghua zhong liu za zhi [Chinese journal of oncology]·2022

Same author

[Exploration on teaching reform of cancer epidemiology course].

Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]·2022

Same author

[Causes and countermeasures of the rapidly rising burden on cervical cancer in Chinese women].

Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi·2022

Same author

[Fractions and trends of cancer burden attributable to population ageing in China].

Zhonghua zhong liu za zhi [Chinese journal of oncology]·2022

Same author

[Meta-analysis of annual probability of outcome for different cervical disease states].

Zhonghua yi xue za zhi·2021

Same journal

[shRNA-mediated downregulation of TERT inhibits melanoma in vitro and in vivo].

Zhonghua zhong liu za zhi [Chinese journal of oncology]·2026

Same journal

[Exploration on the application of perineal lateral arc-shaped incision in the resection of complex tumors on the lateral side of the pelvic floor].

Zhonghua zhong liu za zhi [Chinese journal of oncology]·2026

Same journal

[Risk stratification assessment of brain metastasis in newly diagnosed non-stage IV breast cancer patients with HER-2-low expression following systemic therapy].

Zhonghua zhong liu za zhi [Chinese journal of oncology]·2026

Same journal

[Clinicopathological analysis of SMARCA4-deficient tumors of digestive system origin].

Zhonghua zhong liu za zhi [Chinese journal of oncology]·2026

Same journal

[cfDNA sequencing reveals response heterogeneity to first-line camrelizumab plus chemotherapy in esophageal squamous cell carcinoma].

Zhonghua zhong liu za zhi [Chinese journal of oncology]·2026

Same journal

[Efficacy and safety of combination immunotherapy for locally advanced esophageal carcinoma].

Zhonghua zhong liu za zhi [Chinese journal of oncology]·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 11, 2026

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

[Expert consensus on liquid biopsy-based multi-cancer early detection (2025 edition)].

W Q Chen¹, K X Chen², Y T He³

¹Working Group for the Development of Expert Consensus on Liquid Biopsy-based Multi-Cancer Early Detection.

Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]

|July 22, 2025

Summary

This summary is machine-generated.

Multi-cancer early detection (MCED) using liquid biopsies offers a less invasive way to find many cancers early. This expert consensus guides research and adoption of MCED for better cancer screening strategies.

More Related Videos

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients

Published on: September 9, 2020

Automatic Separation and Collection of Cancer-Related Substances from Clinical Samples

Automatic Separation and Collection of Cancer-Related Substances from Clinical Samples

Published on: January 13, 2023

Related Experiment Videos

Last Updated: Jun 11, 2026

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients

Published on: September 9, 2020

Automatic Separation and Collection of Cancer-Related Substances from Clinical Samples

Automatic Separation and Collection of Cancer-Related Substances from Clinical Samples

Published on: January 13, 2023

Area of Science:

Oncology and Public Health
Biomarker Discovery
Translational Medicine

Background:

Cancer remains a major global health issue, with current screening limited to specific types and often invasive.
Traditional screening methods face challenges in accuracy, patient compliance, and limited cancer coverage.
Early detection is crucial for reducing cancer mortality, highlighting the need for improved screening strategies.

Framework:

Multi-cancer early detection (MCED) utilizes liquid biopsy to analyze biomarkers (e.g., cell-free DNA, RNA, proteins) in bodily fluids.
This approach enables non-invasive detection of multiple cancer types simultaneously.
MCED broadens the scope of detectable cancers and improves population coverage for screening.

Implementation:

This expert consensus reviews advancements in liquid biopsy-based MCED technologies.
It covers biomarker selection, detection methods, and criteria for choosing target cancer types.
The document also addresses research design, clinical utility evaluation, and pathways for MCED implementation.

Implications:

MCED holds immense potential to revolutionize current cancer screening paradigms.
Scientific guidance is provided to foster further research and promote widespread adoption of MCED.
The ultimate goal is to optimize cancer screening strategies and reduce cancer mortality globally.